[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:hepatocellular-carcinoma:msi1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Hepatocellular Carcinoma","MSI1 Gene",7,[8,16,23,29,35,41,48],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07419841","A Phase 1 Study of the Safety and Tolerability of CTX-10726",[12],"Phase 1","RECRUITING","2026-08-26T02:18:55.570428Z","2026-07-05T05:32:16.684256Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03539822","Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:58.141497Z","2026-05-05T02:43:26.745155Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07354100","Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy",[20],"2026-08-26T02:18:52.966503Z","2026-06-17T02:29:30.060269Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05176483","Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors",[12],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.678164Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06362369","A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",[20],"2026-08-26T02:19:22.562392Z","2026-05-05T02:43:27.135162Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT04114136","Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies",[45],"Phase 2","2026-08-26T02:18:18.766496Z","2026-05-05T02:43:26.717214Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05086692","A Beta-only IL-2 ImmunoTherapY Study",[20],"2026-08-26T02:18:31.164304Z","2026-05-05T02:35:31.708594Z"]